Luca Giliberto, MD, PhD’s approach to medicine, neurology and Alzheimer’s disease (AD) has always been dual: Basic research and clinical practice. The journey started during medical school where he was exposed to the genetics of AD, and to the intricacies of its pathology. During residency, he worked on the properties of Amyloid beta peptides (Ab) as signaling molecules, dissecting some of the pathways involved in its biology, including its role and regulation by oxidative stress. Since then, he’s had the privilege to work with great mentors and collaborators, such as Massimo Tabaton, George Perry, Mark Smith, Pierluigi Gambetti, Antonio Uccelli, Luciano D’Adamio, Peter Davies and many more. During his PhD, Dr. Giliberto trained in the laboratory of Dr. Luciano D’Adamio at Albert Einstein College of Medicine, where he conducted extensive screening of interactors of the Amyloid Precursor Protein (APP), and identified numerous candidates which can modulate the trafficking and processing of APP. Among them, ITMB2 (BRI2), a modulator of APP physiology. Working at the Feinstein Institutes, Dr. Giliberto was able to interact and collaborate with a diverse range of excellent scientists and expand the focus of his research to tau, immune-response in Alzheimer’s disease, cell cycle and the approach to treat tau pathology with engineered antibodies.
Along with basic research, Dr. Giliberto works with patients affected by Alzheimer’s disease and other dementias, providing clinical care, offering clinical trials, and helping them and their families to cope with the disruption that this disease brings to their lives. This dual role has allowed him to broaden his view of the disease, as the inspiration he receives from patients at every encounter is invaluable.
Dr. Giliberto teaches clinical neurology to medical students, neurology and psychiatry residents at Hofstra University and North Shore University Hospital, and trains MD/PhD and PhD students in the laboratory at the Feinstein Institutes.
Dementia Care Specialist, Alzheimer’s and Dementia Care (ADC) Program, Geriatrics and Palliative Medicine
Director at Southern New York Association, New York Health Care Alliance, Audacia Foundation, Inc.
Internal Medicine – American Board of Internal Medicine
Geriatric Medicine – American Board of IM / Geriatric Medicine
Hospice / Palliative Medicine – American Board of IM / Hospice and Palliative Med
Chief of Division – Geriatric and Palliative Care Medicine, Department of Medicine, Long Island Jewish Medical Center
Chief of Division – Geriatric and Palliative Care Medicine, Department of Medicine, North Shore University Hospital
Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
New York Medical College
Weill Cornell Medical College – New York Hospital
Mount Sinai School of Medicine
Professionally, I am highly motivated and dedicated to making significant contributions to advancing Neuroradiology research and practice. Specifically, I have developed a special focus on neurological molecular imaging, with an emphasis on the advancement of brain PET/MRI and hybrid imaging techniques in dementia and neurodegenerative disease.
I was awarded the Foundation of the ASNR 2021 Boerger Research Fund for Alzheimer s Disease and Neurocognitive Disorders for the project [18F] PI-2620 in Primary Progressive Aphasia (Franceschi AM, PI), with the goal of characterizing biodistribution of abnormal tau accumulation in PPA subtypes using the novel second generation tracer PI-2620 and correlating these findings with clinical disease severity and neurodegeneration. I am also PI for the project Utility of [18F] PI-2620 as Universal Biomarker for the A/T/N Classification of Dementia and Neurodegenerative Disease , which aims to establish the efficacy of PI-2620 as a single, universal biomarker for the A/T/N classification scheme of dementia, with the eventual goal of its use in descriptive classification, patient selection and target engagement assessment in disease-modifying clinical treatment trials. I contribute as a co-Investigator on the study A Life Course Approach to Integrating Trauma and Cognitive Aging: A Cohort of 9/11 Responders, which is part of the World Trade Center (WTC) responders aging program (NIH R01 AG049953; Clouston, PI). This research focuses on PTSD and WTC exposures as risk factors for cognitive dysfunction and decline in a prospective cohort of responders, alongside changes in -amyloid, tau deposition, and neurodegeneration.
These varied experiences have allowed me to understand the characterization of non-Alzheimer s tauopathies, and have improved my analytical expertise to apply this knowledge to studying Alzheimer s disease and related neurocognitive disorders. In addition to multiple scientific publications on these topics, I am lead editor of the textbook Hybrid PET/MR Neuroimaging: A Comprehensive Approach (Springer Nature, 2022).
Dr. Freudenberg-Hua is an associate professor of psychiatry, molecular medicine and genetics in the Feinstein Institutes’ Litwin-Zucker Alzheimer’s Research Center and the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. She is also an attending psychiatrist at the Geriatric Center at the Zucker Hillside Hospital.
Dr. Freudenberg-Hua received her medical degree from the University of Hamburg in Germany. Following clinical and research work in Medical Genetics at the University of Bonn School of Medicine, she completed her medical specialization in General and Geriatric Psychiatry at Hofstra Northwell School of Medicine.
Bio Coming Soon!
Internal Medicine – American Board of Internal Medicine
Geriatric Medicine – American Board of IM / Geriatric Medicine
Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Ross University School of Medicine
NYU Langone Hospital Brooklyn
North Shore University Hospital
Columbia University College-Physicians & Surgeons
Marc L. Gordon, MD, is chief of neurology at Zucker Hillside Hospital and professor of neurology and psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. He received his BA and MA from the State University of New York at Buffalo and his MD from Columbia University, College of Physicians & Surgeons. He completed his neurology residency training and a fellowship in neuropsychopharmacology at Albert Einstein College of Medicine in 1990. Dr. Gordon is a diplomate of the American Board of Psychiatry and Neurology and a fellow of the American Academy of Neurology.
Paul J. Mattis, PhD, ABPP-CN, specializes in neuropsychology, which is concerned with the relationship between cognition and brain functioning. Many neurological, psychiatric and medical disorders are associated with changes in cognitive functioning, evident by the symptoms such as trouble remembering, inability to pay attention, and inefficient communication. In turn, these deficits are associated with decreased everyday functioning and declining quality of life.
Senior Vice President and Executive Director, Neurology Service Line Northwell Health
Co-Director, Institute for Neurology and Neurosurgery
Chair of Neurology
North Shore University Hospital, Long Island Jewish Medical Center, Lenox Hill Hospital and Staten Island University Hospital
Medical Director, Center for Executive and Global Health Services
Internationally recognized for his clinical, research and teaching expertise, Souhel Najjar, MD, has dedicated his career to diagnosing and treating epilepsy of all ages, complex neurological disorders, and autoimmune disorders of the peripheral and the central nervous system. As Co-Director of the Northwell’s Institute for Neurology and Neurosurgery, Dr. Najjar directs a multidisciplinary team of experts shaping the field of neuroscience. Under his leadership, the Team’s accomplishments include our hospitals’ continued preeminent rankings in US News and World Report, top accreditation by the National Association of Epilepsy Centers and The Joint Commission and NYS Accreditation of 2 Comprehensive Stroke Centers, 15 Department of Health Primary Centers; creating the first of its kind inpatient Parkinson’s Program, and developing our Memory Disorders and Headache Centers. Founder of the Autoimmune Brain Disorders and Autoimmune Encephalitis Center, he is internationally recognized for his expertise in diagnosing and managing complex CNS autoimmune disorders attracting patients from all over the world. Serving as Chief Medical Director for the Center for Executive and Global Services, Dr. Najjar brings our world-class practices to medical professionals worldwide.
MD – Damascus University Faculty of Medicine
Anatomic/Clinical Pathology – Albany Medical Center Hospital; Neurology – Albany Medical Center Hospital
EEG/Epilepsy – New York University; Neuropathology – New York University
Neurology – American Board of Psychiatry/Neurology
Neuroinflammation and Epilepsy; Neuroinflammation and Psychiatric Illnesses; Autoimmune Encephalitis
Top Doctors, New York Magazine, 2010-2021; Medal of Honor, Ellis Island Honors Society, 2020; Renaissance Award, Wagner College DaVinci Society, 2019; Maxwell J. Schleifer Distinguished Service Award, Exceptional Parent Magazine, 2015
Medical Advisory Board Member, Autoimmune Encephalitis Alliance, Durham, NC; Board Member of Scientific Planning Committee, Psychoimmunology Expert Meetings, Günsberg, Germany; Co-Director, Scientific Planning Committee, Autoimmune Encephalitis Alliance
Pollak TA, Lennox BR, Najjar S, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry. 2020 Jan;7(1):93-108. doi: 10.1016/S2215-0366(19)30290-1. Epub 2019 Oct 24. Erratum in: Lancet Psychiatry. 2019 Dec;6(12):e31. PMID: 31669058.
Neurophysiology; EEG/Epilepsy; Neurology
Neurology; EEG/ Epilepsy; Clinical Neurophysiology; Autoimmune Disorders of the Central Nervous System
North Shore University Hospital; Lenox Hill Hospital; Staten Island University Hospital; Long Island Jewish Medical Center
Neurology Clinical Pharmacist
Dr. Joe Verghese graduated from St. Johns Medical College, Bangalore, India in 1989. He did his postgraduate training in Internal Medicine and Neurology in United Kingdom. He completed his Neurology residency at the Albert Einstein College of Medicine, Bronx, NY in 1998. He did his fellowship training in Neurophysiology as well as Aging & Dementia in 1999 at the same institution. He received a Master of Science degree in Clinical Research Methods with Distinction in 2001. Dr Verghese is board-Certified in Neurology.
Dr. Verghese is Professor of Neurology and Medicine, Murray D. Gross Memorial Faculty Scholar in Gerontology, and Director, Resnick Gerontology Center at Einstein. He is the Chief of the Integrated Divisions of Cognitive and Motor Aging (Neurology) and Geriatrics (Medicine).
Dr. Verghese is a recipient of the Beeson award from the National institute on Aging and the Outstanding Scientific Achievement for Clinical Investigation Award from the American Geriatrics Society. His research interest is the effects of disease and aging on mobility and cognition in older adults. He has over 200 peer-reviewed publications and several federally funded grants in this area. His current projects include studying the influence of cognitively stimulating activities on reducing risk of dementia, the role of divided attention tasks such as walking while talking in predicting outcomes such as disability and cognitive decline, cognitive interventions, and global health.
Institute for Neurology and Neurosurgery
Kelly Wexlar serves as Program Director for Northwell Health’s Neurosciences. Kelly leads the program’s Continuing Medical Education and community outreach events throughout New York. She also builds Northwell Neurosciences’ presence in our medical and patient communities through marketing, PR, corporate partnerships, and various initiatives across the health system.
Receiving an M.B.A from Fordham University, Kelly previously worked at The Boston Consulting Group for the firm’s global Private Equity and Principal Investors group. Kelly is deeply passionate about bringing diverse perspectives to neurosciences and committed to further innovating the department by leveraging new thought leadership and cutting-edge technologies shaping the field.